Original article
English
Abdulhamid A. Al-Tubuly*, Mary A. Ritter**
*Department of Medical Micribiology and Immunology, Faculty of Medicine, Elfateh Univesity, Tripoli, Libya
**Department of Immunology, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London, UK
JMJ Vol. 2, No. 3 (March 2003): 31-36
Abstract
The monoclonal antibody (MAb) MR6 was raised against thymic cortical epithelial cells in a study designed to analyse the role of thymic microenvironment in T-cell development. MAb MR6 recognizes a transmembrane molecule of 200 kDa (gp200-MR6), which is functionally associated with the interlukin-4 receptor (Il-4R), and has been recently designated “CD205”. Gp200-MR6 was found to be expressed strongly on all in all normal epithelial tissue studied. Interestingly, the expression was found to be less strongly on benign hyperplasia of the breast, and disappeared altogether on highly malignant invasive tumours which suggest a key role for gp200-MR6 (CD205) molecule on prostatic epithelial cells which has the highest frequency of any organ for manifesting benign hyperplasia. Our data show that prostatic epithelial cells do not express the molecule gp200-MR6 which may explain the high incidence of hyperplasia and subsequent tumour development in this tissue.
Keywords: Monoclonal Antibody, Cortical epithelium, Hyperplasia, prostate
Link/DOI: http://www.jmj.org.ly/modules.php?name=News&file=article&sid=1258